These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 26687836)

  • 1. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
    Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
    Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
    BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
    Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
    J Clin Oncol; 2010 Mar; 28(7):1247-53. PubMed ID: 20124181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet.
    Pantaleo MA; Nannini M
    Eur J Cancer; 2016 May; 58():38-40. PubMed ID: 26933960
    [No Abstract]   [Full Text] [Related]  

  • 10. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
    Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
    Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ; Shan YS; Yang CY; Hsiao CF; Tsai CH; Wang CC; Lin MT; Ting CF; Chan DC; Chen TH; Yen CC; Chen YY; Lin HY; Yeh TS; Ho CL; Shieh TY; Bai LY; Hsu JT; Chen IS; Chen LT; Yeh CN;
    BMC Cancer; 2024 Jul; 24(1):828. PubMed ID: 38992597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
    Gao J; Dang Y; Sun N; Li J; Shen L
    Med Oncol; 2012 Dec; 29(5):3039-45. PubMed ID: 22815156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with
    George S; Blay JY; Chi P; Jones RL; Serrano C; Somaiah N; Gelderblom H; Zalcberg JR; Reichmann W; Sprott K; Cox P; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S
    Future Oncol; 2024; 20(27):1973-1982. PubMed ID: 39229786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.
    Shen YY; Ma XL; Wang M; Zhuang C; Ni B; Tu L; Liu Q; Zhao WY; Cao H
    Cancer Med; 2020 Sep; 9(18):6485-6496. PubMed ID: 32697050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.